The effects have been complicated by uneven distribution of ApoE4 carriers among placebo and therapy teams, which was brought on by an EMA request in the course of the trial. A subgroup Investigation, introduced at CTAD, suggested that the procedure gain was not as a consequence of this imbalance (N… Read More